Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel small molecule therapeutics. The company's core business revolves around selectively degrading disease-causing proteins by harnessing the body's natural protein degradation system, utilizing its proprietary Targeted Protein Degradation (TPD) platform, Pegasus™. Its mission is to reinvent the treatment of human disease and build a global medicines company that revolutionizes healthcare through novel modalities. Kymera Therapeutics is headquartered in Watertown, Massachusetts.

The company's pipeline focuses on deploying TPD against disease targets in areas of significant patient need, primarily in immunology and oncology. Key product candidates include KT-621, an oral STAT6 degrader for Type 2 inflammatory diseases such as atopic dermatitis and eosinophilic asthma, and KT-579, an IRF5 degrader targeting autoimmune diseases like lupus and rheumatoid arthritis. Kymera also has partnered programs, such as KT-485, an IRAK4 degrader in collaboration with Sanofi for immuno-inflammatory diseases, and KT-200, a CDK2 molecular glue degrader with Gilead Sciences for oncology applications, including breast cancer.

In recent news, Kymera Therapeutics reported strong first-quarter 2026 revenue, surpassing analyst expectations, largely driven by its collaboration with Gilead Sciences. Gilead Sciences exercised its option to license KT-200, triggering a $45 million milestone payment in Q2 2026. The U.S. FDA granted Fast Track designation for KT-621 in moderate to severe eosinophilic asthma in April 2026. Led by Founder, President, and CEO Nello Mainolfi, Ph.D., the company maintains a cash runway projected into 2029, supporting its expanding clinical pipeline.

Latest updates

Kymera Therapeutics Lands Gilead Milestone, Pipeline Data Looms

Event summary

  • Kymera Therapeutics received a $45 million milestone payment from Gilead Sciences following the latter's option exercise to license the CDK2 molecular glue degrader, KT-200.
  • The company maintains $1.55 billion in cash, projecting a runway into 2029.
  • Phase 2b trials (BROADEN2 for atopic dermatitis and BREADTH for asthma) are ongoing, with data expected in mid-2027 and late 2027, respectively.
  • A Phase 1 trial for KT-579 (IRF5 degrader) is underway, with data expected in the second half of 2026.

The big picture

Kymera’s progress highlights the growing interest in targeted protein degradation as a therapeutic modality, particularly within immunology. The Gilead partnership validates this approach and provides a significant financial boost. However, the company's valuation remains heavily reliant on the success of its clinical programs, and the timing of data readouts will be a key driver of investor sentiment.

What we're watching

Clinical Execution
The success of the ongoing Phase 2b trials for KT-621 will be critical for establishing efficacy and securing future development and commercialization opportunities, particularly given the large patient populations targeted.
Partner Dynamics
Gilead's progress with KT-200, and any potential expansion of their collaboration, will indicate the value they place on Kymera’s degrader technology and could influence future partnership decisions.
Pipeline Expansion
The company's ability to advance at least one new development candidate into IND stage by 2026 will demonstrate the robustness of its target selection and discovery platform, and its ability to sustain long-term growth.
CID: 1778